BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced solid second quarter 2008 financial results. For the three months ended June 30, 2008, Enzon reported a net loss of $1.7 million or $0.04 on a diluted per-share basis, as compared to a net loss of $2.0 million or $0.04 per diluted share for the second quarter of 2007. The Company’s results continue to be positively impacted by strong revenues across all business segments.
